Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Elbit Systems Ltd.
ESLT·Industrials
B ★★★Hold
Current$681.98
Target$656.88
Return-3.7%
Nov 20, 2026

Elbit Systems benefits from sustained global defense spending, record backlog, and improving profitability, but its elevated valuation and geopolitical exposure limit the margin of safety for new investors.

Score
66
Hudbay Minerals Inc.
HBM·Materials
B ★★★Hold
Current$21.38
Target$28.10
Return+31.4%
Nov 15, 2026

Hudbay Minerals offers diversified copper-gold cash generation and substantial U.S. copper growth potential, but commodity volatility, heavy development spending, and acquisition-related dilution constrain its margin of safety.

Score
66
CAE Inc.
CAE·Industrials
B ★★★Hold
Current$27.93
Target$31.32
Return+12.1%
Nov 14, 2026

CAE benefits from durable aviation training demand and improving defense profitability, but capital-intensive operations, weak Civil margins, and demanding earnings expectations limit near-term investment upside.

Score
66
Liquidia Corporation
LQDA·Healthcare
B ★★★Hold
Current$58.12
Target$57.86
Return-0.4%
Nov 13, 2026

Liquidia's rapid YUTREPIA commercialization and high-margin PAH franchise offer substantial earnings potential, but product concentration, litigation settlement costs, and growth normalization limit near-term upside.

Score
66
National Health Investors, Inc.
NHI·Real Estate
B ★★★Hold
Current$66.02
Target$70.70
Return+7.1%
Nov 12, 2026

National Health Investors offers recurring healthcare property income and demographic-driven senior housing growth, but SHOP execution challenges and weaker normalized FFO per share constrain near-term upside.

Score
66
Csquare, Inc.
CSQR·Technology
B ★★★Hold
Current$17.04
Target$22.99
Return+34.9%
Nov 12, 2026

Csquare offers accelerating growth in contracted data center infrastructure demand and improving adjusted operating margins, but substantial leverage, negative free cash flow and future share supply constrain the investment case.

Score
66
JBS N.V.
JBS·Consumer Staples
B ★★★Hold
Current$12.45
Target$14.85
Return+19.3%
Nov 12, 2026

JBS offers a diversified global protein platform with meaningful earnings recovery potential, but elevated leverage, weak cash conversion, and volatile livestock-processing margins constrain near-term upside.

Score
66
Hims & Hers Health, Inc.
HIMS·Healthcare
B ★★★Hold
Current$20.81
Target$26.54
Return+27.5%
Nov 12, 2026

Hims & Hers offers long-term growth through personalized digital healthcare and international expansion, but deteriorating gross margins, weak cash conversion, and pharmaceutical dependence threaten sustainable shareholder returns.

Score
66
Protagonist Therapeutics, Inc.
PTGX·Healthcare
B ★★★Hold
Current$135.90
Target$162.80
Return+19.8%
Nov 10, 2026

Protagonist Therapeutics has transformed two innovative peptide drugs into approved royalty-generating franchises with substantial pipeline upside, but milestone-heavy earnings, commercialization uncertainty, and dilution constrain the investment case.

Score
66
Ameren Corporation
AEE·Utilities
B ★★★Hold
Current$112.65
Target$116.00
Return+3.0%
Nov 10, 2026

Ameren's regulated utility franchise and contracted electricity-demand growth support durable earnings expansion, but heavy capital spending, shareholder dilution and regulatory uncertainty limit the stock's margin of safety.

Score
66
People Incorporated
PPLI·Communication Services
B ★★★Hold
Current$43.38
Target$47.28
Return+9.0%
Nov 10, 2026

People's MGM investment, established publishing brands, and restructuring-led cost savings create an asset-backed value opportunity, although AI-driven traffic disruption and concentrated investment exposure limit conviction.

Score
66